Financings in Brief: Collagen
This article was originally published in The Gray Sheet
Executive Summary
Collagen: Remaining shares of tissue adhesive and anti-adhesion product firm Cohesion Corp. not already owned are acquired for approximately $10 mil. Collagen, which had increased its stake in the privately held company to roughly 80% last year ("The Gray Sheet" June 3, 1996, p. 8), plans to make Cohesion the "centerpiece" of its Collagen Technologies R&D business -- which is scheduled to be spun off to Collagen shareholders as a separate company in 1998 ("The Gray Sheet" Nov. 3, In Brief). The new company, to be renamed Cohesion Technologies, plans to commence U.S. studies of its lead product candidate, the CoStasis "sprayable" hemostatic device (formerly CollaSeal), for multiple indications in 1998. The firm recently commenced European studies of the device for use in cardiothoracic indications...
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.